Ledger.Open graph →
SEC Form D · filed February 21, 2025

Kestrel Therapeutics Inc

Offering
$16.0M
Sold
$8.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Boston, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (18)

Frank G. Haluska · Boston, MAExec · DirectorAndrew G. Phillips · Boston, MADirectorOmar G. Khalil · Boston, MADirectorDenis G. Patrick · Boston, MADirectorBarbara G. Sosnowski · Boston, MADirectorNicholas G. Saccomano · Boston, MADirectorBarbara G. Sosnowski · Boston, MADirectorNicholas G. Saccomano · Boston, MADirectorFrank G. Haluska · Boston, MAExec · DirectorDenis G. Patrick · Boston, MADirectorOmar G. Khalil · Boston, MADirectorAndrew G. Phillips · Boston, MADirectorFred D. Clark · Fern Park, FLDirectorAaron Dillon · NEW YORK, NYDirectorDavid Barker · Fern Park, FLExec · DirectorRichard Ungaro · Fern Park, FLDirectorHarrison L. Hodges · Fern Park, FLDirectorChad L. Mcghee · Fern Park, FLDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗